Quoin Pharmaceuticals, Ltd.

Quoin Pharmaceuticals, Ltd. is a clinical-stage specialty pharmaceutical company dedicated to the development and commercialization of therapeutic products for rare and orphan diseases. Headquartered in Ashburn, Virginia, United States, the company's mission is to address critical, unmet medical needs for patients, their families, communities, and care teams by bringing hope where there is currently none.

The company's innovative pipeline focuses on a broad range of rare and orphan indications, particularly dermatological conditions. Its lead product candidate, QRX003, is a topical lotion currently in late-stage clinical trials for the treatment of Netherton Syndrome, a rare hereditary skin disease. Quoin Pharmaceuticals is also developing other product candidates, including QRX004 for recessive dystrophic epidermolysis bullosa and QRX008 for scleroderma, with additional indications such as Peeling Skin Syndrome, Ichthyosis, Microcystic Lymphatic Malformations, Venous Malformations, Angiofibromas, and SAM Syndrome also being targeted.

In recent news, the U.S. FDA granted Fast Track Designation for QRX003 for Netherton Syndrome on March 11, 2026, facilitating its development and expediting regulatory review. The company is targeting approval for QRX003 in 2027 and has reported a private placement financing of up to $104.5 million in its Q4 and full-year 2025 updates. Led by Co-Founder, Chairman, and CEO Dr. Michael Myers, alongside Co-Founder and COO Denise Carter, Quoin Pharmaceuticals plans to establish commercial infrastructure in the U.S., Western Europe, and Japan, complemented by strategic commercial agreements spanning 61 countries.

Latest updates

Quoin Pharmaceuticals to Detail Q1 2026 Performance Amidst Orphan Disease Pipeline

Event summary

  • Quoin Pharmaceuticals (NASDAQ: QNRX) will release its Q1 2026 financial results and a corporate update on May 7, 2026.
  • The company focuses on developing therapeutics for rare and orphan diseases.
  • Quoin’s pipeline includes QRX003 and QRX009, targeting conditions like Netherton Syndrome and venous malformations.
  • Dr. Michael Myers, Ph.D. serves as CEO of Quoin Pharmaceuticals Ltd.

The big picture

Quoin Pharmaceuticals operates in a sector characterized by high R&D costs and lengthy regulatory approval processes. The company’s focus on orphan diseases presents a niche market opportunity, but also exposes it to challenges related to patient access and reimbursement. The upcoming update will provide insight into how Quoin is navigating these complexities and advancing its pipeline.

What we're watching

Pipeline Progress
The operational update will likely detail progress on QRX003 and QRX009, and the market should assess whether these developments align with previously stated timelines and milestones.
Financial Runway
Given the capital intensity of late-stage clinical development, the Q1 2026 financials will be scrutinized to determine Quoin’s remaining cash runway and potential need for future financing.
Regulatory Landscape
The success of Quoin’s pipeline hinges on regulatory approvals; the company’s commentary on the evolving regulatory environment for orphan drugs will be a key indicator of future prospects.

Quoin Expands Rare Disease Pipeline with Investigator-Led Trials, Aims for Q3 IND Filing

Event summary

  • Quoin Pharmaceuticals plans investigator-led clinical studies for QRX009 in Pachyonychia Congenita (PC), Gorlin Syndrome (GS), and Tuberous Sclerosis Complex (TSC), starting in Q3 2026.
  • The PC study will be led by Professor Edel O’Toole of Queen Mary University of London.
  • Quoin intends to submit an Investigational New Drug Application (IND) for QRX009 to the FDA for an additional indication in Q3 2026.
  • The company has established relationships with advocacy foundations and key opinion leaders (KOLs) in the rare disease space.

The big picture

Quoin’s strategy of leveraging investigator-led trials is a common approach for rare disease drug development, allowing for broader exploration of indications with limited commercial incentive for traditional, company-sponsored studies. This approach reduces upfront costs but introduces dependencies on external researchers and potential delays. The company’s focus on multiple indications reflects a broader trend in the rare disease space towards identifying niche applications for existing compounds, aiming to maximize return on investment.

What we're watching

Execution Risk
The success of the investigator-led trials hinges on Professor O’Toole’s expertise and the ability of other clinicians to enroll patients and generate meaningful data within a reasonable timeframe.
Regulatory Scrutiny
The FDA’s review of the upcoming IND submission will be critical, and any delays or requests for additional data could impact Quoin’s timeline for QRX009.
Pipeline Diversification
How effectively Quoin manages the complexity of multiple, concurrent clinical programs – across PC, GS, TSC, and others – will determine its ability to capitalize on the potential of QRX009.

Quoin Expands Rare Disease Pipeline with Investigator-Led Studies, IND Filing

Event summary

  • Quoin Pharmaceuticals plans investigator-led clinical studies for QRX009 in Pachyonychia Congenita (PC), Gorlin Syndrome (GS), and Tuberous Sclerosis Complex (TSC), starting in Q3 2026.
  • Professor Edel O’Toole of Queen Mary University of London will lead the PC study, leveraging her expertise in the disease.
  • Quoin intends to file an Investigational New Drug (IND) application with the FDA for an additional QRX009 indication in Q3 2026.
  • The company has established relationships with patient advocacy groups and key opinion leaders (KOLs) in the rare disease space.

The big picture

Quoin’s strategy of leveraging investigator-led trials represents a cost-effective approach to expanding the potential indications for QRX009, particularly in rare diseases where traditional clinical trial infrastructure is limited. This model relies heavily on external expertise and patient advocacy groups, which can accelerate development but also introduces dependencies on third parties. The planned IND submission signals a continued focus on broadening the therapeutic applications of QRX009 beyond its lead indication in Netherton Syndrome.

What we're watching

Clinical Execution
The success of the investigator-led studies will hinge on patient recruitment and data quality, potentially impacting the timeline for future regulatory submissions.
Regulatory Risk
The FDA’s response to the upcoming IND application will be crucial, and any delays or requests for additional data could significantly impact Quoin’s development timeline.
Pipeline Breadth
The company's ability to simultaneously manage multiple clinical trials across diverse indications will test its operational capacity and resource allocation.
CID: 1721